32 related articles for article (PubMed ID: 23503443)
1. Pharmacokinetic Variability of Sulthiame: The Impact of Age, Drug-Drug Interactions, and Biochemical Markers of Toxicity in Patients with Epilepsy.
Heger K; Kjeldstadli K; Ring N; Aaberg KM; Kjeldsen SF; Burns ML; Johannessen SI; Johannessen Landmark C
Ther Drug Monit; 2024 Apr; 46(2):237-245. PubMed ID: 38158595
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic Variability of Rufinamide and Stiripentol in Children with Refractory Epilepsy: A Retrospective Study of Therapeutic Drug Monitoring from the National Epilepsy Centers in Denmark and Norway.
Heger K; Burns ML; Nikanorova M; Johannessen SI; Johannessen Landmark C
Ther Drug Monit; 2024 May; ():. PubMed ID: 38758628
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of adherence to headache treatments by means of hair analysis.
Ferrari A; Licata M; Rustichelli C; Baraldi C; Vandelli D; Marchesi F; Palazzoli F; Verri P; Silingardi E
Eur J Clin Pharmacol; 2017 Feb; 73(2):197-203. PubMed ID: 27866243
[TBL] [Abstract][Full Text] [Related]
4. Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs.
Patsalos PN
Clin Pharmacokinet; 2013 Nov; 52(11):927-66. PubMed ID: 23784470
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication.
Johannessen Landmark C; Baftiu A; Tysse I; Valsø B; Larsson PG; Rytter E; Johannessen SI
Ther Drug Monit; 2012 Aug; 34(4):440-5. PubMed ID: 22777154
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring of topiramate by liquid chromatography-tandem mass spectrometry.
Matar KM
Clin Chim Acta; 2010 May; 411(9-10):729-34. PubMed ID: 20138857
[TBL] [Abstract][Full Text] [Related]
7. Cognitive profile of topiramate as compared with lamotrigine in epilepsy patients on antiepileptic drug polytherapy: relationships to blood serum levels and comedication.
Kockelmann E; Elger CE; Helmstaedter C
Epilepsy Behav; 2004 Oct; 5(5):716-21. PubMed ID: 15380124
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with topiramate dosing and serum levels in patients with epilepsy.
Zanotta N; Raggi ME; Radice L; Degrate A; Bresolin N; Zucca C
Seizure; 2006 Mar; 15(2):86-92. PubMed ID: 16406695
[TBL] [Abstract][Full Text] [Related]
9. Effect of CYP Inducers/Inhibitors on Topiramate Concentration: Clinical Value of Therapeutic Drug Monitoring.
Yamamoto Y; Takahashi Y; Imai K; Kagawa Y; Inoue Y
Ther Drug Monit; 2017 Feb; 39(1):55-61. PubMed ID: 27941476
[TBL] [Abstract][Full Text] [Related]
10. Factors influencing serum topiramate concentrations in routine therapeutic drug monitoring in Korean adult patients with epilepsy.
Huh HJ; Joo EY; Hong SB; Ahn JH; Seo DW; Lee SY
Ther Drug Monit; 2013 Apr; 35(2):177-82. PubMed ID: 23503443
[TBL] [Abstract][Full Text] [Related]
11. Is there a role for therapeutic drug monitoring of new anticonvulsants?
Perucca E
Clin Pharmacokinet; 2000 Mar; 38(3):191-204. PubMed ID: 10749516
[TBL] [Abstract][Full Text] [Related]
12. [Monitoring serum levels of new antiepileptics].
Armijo JA; Adín-Ibarra J; Sánchez-Baglietto N; Vega-Gil N
Rev Neurol; 2002 Sep; 35 Suppl 1():S116-34. PubMed ID: 12373664
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
